Skip to main
  1. Stocks
  2. PTC Therapeutics
  3. Forecast
PTCT

PTC Therapeutics (PTCT) Stock Forecast & Price Target

PTC Therapeutics (PTCT) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

PTC Therapeutics is benefiting from a powerful commercial inflection, as Sephience sales of $181.9MM beat consensus and drove Q3 total revenue to $357.8MM, while FY2026 product revenue guidance was raised to $960MM-$990MM and total revenue guidance to $1.29B-$1.32B. The launch appears durable and broadening, with over 2,000 active patients worldwide, ~90% renewal rates, increasing switch uptake, and continued geographic expansion across the U.S., EU, Japan, and other markets, supporting management’s view that Sephience could ultimately become a $2B+ product. Beyond PKU, the company has additional upside from a well-capitalized balance sheet with $2.13B in cash and a deep pipeline, including ST-920 with a rolling BLA expected in Q4:26, votoplam, and earlier-stage programs that can extend growth.

Bears say

PTC Therapeutics is pressured by weakening legacy revenue streams, with Emflaza Q3 sales of $25.1MM still down 28.7% Y/Y and expected 2026 sales of $87.6MM, down 40% Y/Y, while low-price generic erosion and competition continue to weigh on its DMD franchise. Its regulatory profile is also deteriorating: Translarna lost EU market authorization in March 2025, and vatiquinone received a CRL on August 19, 2025 after the FDA said the efficacy package was insufficient, forcing additional studies and delaying any resubmission path. With substantial international exposure, persistent clinical-trial risk, and uncertainty around pipeline conversion, the company faces a difficult outlook if newer assets fail to offset declining commercial products.

PTC Therapeutics (PTCT) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PTC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

PTC Therapeutics (PTCT) Analyst Forecast & Price Prediction

Get the latest PTC Therapeutics (PTCT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PTC Therapeutics (PTCT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PTC Therapeutics (PTCT) Forecast

Analysts have given PTC Therapeutics (PTCT) a Buy based on their latest research and market trends.

According to 11 analysts, PTC Therapeutics (PTCT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PTC Therapeutics (PTCT)


PTC Therapeutics (PTCT) Analyst Forecast & Price Prediction

Get the latest PTC Therapeutics (PTCT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PTC Therapeutics (PTCT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PTCT stock data and trends